At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 370 enrolled
Drug / intervention
DE-117 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared With Latanoprost Ophthalmic Solution 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension- PEONY Study
In Brief
A Phase 3 clinical trial evaluating DE-117 and Latanoprost ophthalmic solution for Open Angle Glaucoma or Ocular Hypertension. Completed, enrolled 370 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSingapore
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartJan 2017
Primary CompletionJan 2019
TodayJul 2026
First PostedDec 5, 2016
Enrollment StartJan 1, 2017
Primary CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.6 years ago
Interventions
DE-117drug
DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
Latanoprost ophthalmic solutiondrug
Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.